Key result
Quinapril-containing regimens reduced the primary composite of doubling creatinine, renal replacement therapy, or death compared to amlodipine in a per-protocol analysis (p=0.038).
Why the study?
Does quinapril compared to amlodipine reduce the composite of doubling serum creatinine, starting renal replacement therapy, or death in hypertensive patients with progressive non-diabetic nephropathies?
Population
73 hypertensive patients with progressive non-diabetic nephropathies
Comparison
Quinapril alone or Quinapril + Amlodipine… vs Amlodipine alone, titrated to achieve a…
Design
RCT, prospectively randomised, open-label
Follow-up
4 years or until death
Authors
Loading...
Supports quinapril over amlodipine for renal outcomes in per-protocol analysis; extends ACEI evidence in non-diabetic nephropathy but tolerability limits adoption.
RCT (n=73)
Open-label
Does quinapril compared to amlodipine reduce the composite of doubling serum creatinine, starting renal replacement therapy, or death in hypertensive patients with progressive non-diabetic nephropathies?
p-value: p=NS (ITT); 0.038 (per protocol)
Quinapril may be more effective than amlodipine at reducing the need for dialysis in progressive non-diabetic renal failure, but its clinical utility is severely limited by poor tolerability.
MacGregor et al. (2005) conducted an RCT in Progressive non-diabetic nephropathies and hypertension (n=73). Quinapril and/or Amlodipine vs. Amlodipine was evaluated on Combined endpoint of doubling serum creatinine, starting renal replacement therapy or death (p=NS (ITT); 0.038 (per protocol)). Quinapril-containing regimens reduced the primary composite of doubling creatinine, renal replacement therapy, or death compared to amlodipine in a per-protocol analysis (p=0.038).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: